Amarin Corp Plc (AMRN)

[sts66]

Call me a skeptic - it took 21 yrs to get to this point - and if it were really viable, it's value would have had BP all over it years ago - specifically, what did they measure and what did they "expect"?

https://www.jqknews.com/news/44287-Conquer_the_key_step_of_Alzheimers_disease_The_new_drug_completes_the_phase_3_clinical_trial.html

The 3 phase of the clinical trial of GV-971 was a randomized, double-blind, placebo controlled 36 week study in China to assess the effectiveness and safety of GV-971 in patients with mild to moderate Alzheimers disease (the simple mental state examination scale score of 11-26). During the clinical study, the patients took 450 mg of oral medicine, two times a day. The main efficacy end point was the change in the cognitive part of Alzheimers disease rating scale after 36 weeks. The results showed that GV-971 achieved the expected effect on cognitive function improvement, and had significant statistical significance and clinical significance. The incidence of adverse events was very similar to that of placebo. In particular, no side effects of abnormal amyloid associated imaging were found.